New MRI dye could sharpen view of heart damage in AF patients

NCT ID NCT07083115

ENROLLING_BY_INVITATION Diagnosis Sponsor: The Cleveland Clinic Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new MRI contrast agent called Gadopiclenol to see if it provides clearer images of heart damage in people with atrial fibrillation (AF). Researchers will compare it to standard contrast agents in 50 AF patients. The goal is to improve diagnosis and guide treatment for AF.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gadopiclenol (a new MRI contrast agent)
What this could lead to: If successful, this could lead to clearer MRI images of heart damage in atrial fibrillation patients, helping doctors diagnose and plan treatment more accurately.
What could go wrong: This is a small, early-phase imaging study focused on image quality, not treatment. The new contrast agent may not prove significantly better than current agents, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION (AF)

Contacts and locations

Locations

Cleveland Clinic

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.